Table 4 Comparison of parameter-response to SGLT2 inhibitor in groups showing high or low response of ACR at 1 M

n = 6

n

n = 6

n

n = 5

n

n = 4

n

%∆ACR

− 62.5 ± 16.3

6

2.0 ± 35.3

**

6

− 51.5 (− 51.7, − 45.9)

5

− 27.9 (− 33.6, − 10.0)

^†

4

%∆BMI

0.0 ± 1.7

6

− 0.8 ± 1.3

6

0.0 (− 0.6, 0.0)

5

0.0 (− 2.6, 1.2)

4

%∆systolic BP

− 7.3 ± 2.0

6

− 2.2 ± 5.0

6

− 6.5 ± 12.2

5

10.0 ± 16.1

4

%∆diastolic BP

− 8.0 ± 7.4

6

− 5.7 ± 6.9

6

− 2.5 ± 7.9

5

7.3 ± 23.8

4

%∆HbA1c

− 2.2 (− 7.1, − 1.5)

6

− 3.5 (− 4.0, 2.6)

6

− 3.9 ± 4.4

5

0.9 ± 4.6

4

%∆HOMA-R

− 36.0 ± 20.0

5

72.0 ± 131.1

4

24.1 ± 51.7

4

− 4.1 ± 22.9

4

%∆Hb

4.6 ± 4.4

5

2.8 ± 3.4

6

2.1 (0.0, 5.4)

5

0.7 (− 0.3, 0.7)

3

%∆eGFR

− 5.3 ± 10.4

6

− 0.8 ± 7.9

6

− 4.9 ± 7.5

5

− 5.4 ± 8.8

4

%∆NTproBNP

50.3 ± 56.8

5

42.7 ± 106.1

5

− 17.2 ± 31.6

4

21.3 ± 21.3

3

%∆FENa

− 29.8 (− 48.5, 36.1)

6

− 14.7 (− 34.2, 9.9)

5

7.8 ± 54.7

5

116.3 ± 176.5

4

%∆NAG/Cr

41.9 ± 72.7

6

28.5 ± 51.3

5

− 12.3 ± 26.4

5

42.7 ± 59.2

3

%∆MCP-1/Cr

16.0 ± 35.2

5

45.8 ± 83.1

5

− 25.7 ± 11.4

5

59.2 ± 17.0

^††

4

%∆iPF2α-III/Cr

14.1 ± 36.6

5

11.2 ± 66.2

6

20.1 ± 50.4

5

− 11.4 ± 17.9

4